



## G1 Therapeutics to Present at the 18th Annual Needham Healthcare Conference

April 2, 2019

RESEARCH TRIANGLE PARK, N.C., April 02, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company overview at the 18<sup>th</sup> Annual Needham Healthcare Conference. The presentation will take place on Tuesday, April 9, at 9:20 a.m. ET at the Westin New York Grand Central in New York, NY.

To access the live webcast presentation, please visit the [Events & Presentations](#) page of the company's website: [www.g1therapeutics.com](http://www.g1therapeutics.com). The webcast will be archived on the same page for 90 days following the event.

### About G1 Therapeutics

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs, [trilaciclib](#), [lerociclib](#) and [G1T48](#), that are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications. G1 also has an active discovery program focused on cyclin-dependent kinases targets.

G1 is based in Research Triangle Park, N.C. For additional information, please visit [www.g1therapeutics.com](http://www.g1therapeutics.com) and follow us on Twitter @G1Therapeutics.

### Contact:

Jeff Macdonald

Head of Investor Relations/Public Relations

919-907-1944

[jmacdonald@g1therapeutics.com](mailto:jmacdonald@g1therapeutics.com)



Source: G1 Therapeutics